Regulators assess PB016 vedolizumab biosimilar applications

Researchers highlight minimally invasive monitoring potential

First-in-human evaluation of infinitopes’ therapeutic platform

First IBAT inhibitor for PBC cholestatic pruritus

Designation supports pivotal trials for emerging candidates

Phase 3 data show strong benefit for two therapies

First patient enrolled in pivotal coronary study

European regulators move closer to approving option for young male patients

New service strengthens UK access to advanced multiomics support

Where the future of workplace wellbeing takes centre stage